Efficacy and Safety of Benvitimod in Patients With Palmoplantar Pustulosis: An Open-Label, Multicenter, Prospective Study

IF 3.7 4区医学 Q1 DERMATOLOGY Dermatologic Therapy Pub Date : 2024-10-22 DOI:10.1155/2024/8829762

Guangping Wang, Shuai Zhang, Huimin Yan, Fang Qi, Bingxin Zhang, Yan Li, Hongmei Wang, Jingna Song, Siyao Wang, Sanwu Zeng, Liming Ji

{"title":"Efficacy and Safety of Benvitimod in Patients With Palmoplantar Pustulosis: An Open-Label, Multicenter, Prospective Study","authors":"Guangping Wang, Shuai Zhang, Huimin Yan, Fang Qi, Bingxin Zhang, Yan Li, Hongmei Wang, Jingna Song, Siyao Wang, Sanwu Zeng, Liming Ji","doi":"10.1155/2024/8829762","DOIUrl":null,"url":null,"abstract":"<div>\n <p>Palmoplantar pustulosis (PPP) is often considered as pustular psoriasis of extremities. Benvitimod has been approved for mild to moderate psoriasis. We thus designed this study to evaluate the efficacy and safety of benvitimod for treating PPP. Of 47 PPP patients recruited from 4 hospitals, 40 finished 8 weeks visit and completed 4 weeks safety follow-up visit. The Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI) and Dermatology Life Quality Index (DLQI) scores fell continuously. At week 8, mean ± SD PPPASI and DLQI were 3.39 ± 3.86 (<i>p</i> < 0.0001) and 2.49 ± 3.34 (<i>p</i> < 0.0001), respectively. At week 8, 70% (28/40) achieved PPPASI-50 response, 35% (14/40) achieved PPPASI-75 response, and 17.5% (7/40) achieved PPPASI-90 response. Relapse occurred in 7.5% (3/40) of the patients. Of 47 patients enrolled, self-reported compliance was 12.77% (6/47). Common drug-related adverse events (5/47) included xerosis cutis. Only one patient’s disease progressed during treatment. Our study demonstrated the efficacy and safety of benvitimod.</p>\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2024 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/8829762","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/8829762","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Palmoplantar pustulosis (PPP) is often considered as pustular psoriasis of extremities. Benvitimod has been approved for mild to moderate psoriasis. We thus designed this study to evaluate the efficacy and safety of benvitimod for treating PPP. Of 47 PPP patients recruited from 4 hospitals, 40 finished 8 weeks visit and completed 4 weeks safety follow-up visit. The Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI) and Dermatology Life Quality Index (DLQI) scores fell continuously. At week 8, mean ± SD PPPASI and DLQI were 3.39 ± 3.86 (p < 0.0001) and 2.49 ± 3.34 (p < 0.0001), respectively. At week 8, 70% (28/40) achieved PPPASI-50 response, 35% (14/40) achieved PPPASI-75 response, and 17.5% (7/40) achieved PPPASI-90 response. Relapse occurred in 7.5% (3/40) of the patients. Of 47 patients enrolled, self-reported compliance was 12.77% (6/47). Common drug-related adverse events (5/47) included xerosis cutis. Only one patient’s disease progressed during treatment. Our study demonstrated the efficacy and safety of benvitimod.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

本维莫德对掌跖脓疱病患者的疗效和安全性：一项开放标签、多中心、前瞻性研究

掌跖脓疱病（PPP）通常被认为是肢端脓疱型银屑病。苯维莫德已被批准用于治疗轻度至中度银屑病。因此，我们设计了这项研究来评估苯维莫德治疗 PPP 的疗效和安全性。从 4 家医院招募的 47 名 PPP 患者中，40 人完成了 8 周的随访，并完成了 4 周的安全随访。掌跖脓疱型银屑病面积和严重程度指数（PPPASI）和皮肤科生活质量指数（DLQI）评分持续下降。第 8 周时，PPPASI 和 DLQI 的平均值（± SD）分别为 3.39 ± 3.86（p < 0.0001）和 2.49 ± 3.34（p < 0.0001）。第8周时，70%（28/40）的患者对PPPASI-50有反应，35%（14/40）的患者对PPPASI-75有反应，17.5%（7/40）的患者对PPPASI-90有反应。7.5%的患者（3/40）出现复发。在入组的 47 名患者中，自我报告的依从性为 12.77%（6/47）。常见的药物相关不良反应（5/47）包括皮肤干燥症。只有一名患者在治疗期间病情恶化。我们的研究证明了苯维莫德的有效性和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.